Opaleye Management Inc’s holdings in Axogen Inc (AXGN) is reduced by 16.03% based on its latest 2018Q2 regulatory filing with the SEC. By selling 275,000 shares Opaleye Management Inc made the stock sank with 27.73%. At the end of 2018Q2, the hedge fund held 1.44 million shares of the health care company, valued at $72.36M, down from 1.72 million at the end of the previous reported quarter. $1.41B is the market cap of Axogen Inc. AXGN is touching $36.38 during the last trading session, after decreased 3.37%.AxoGen, Inc. has volume of 258,481 shares. Since November 10, 2017 AXGN has risen 96.73% and is uptrending. The stock outperformed the S&P500 by 81.11%.
Opaleye Management Inc has risen its stake in and also increased its holding in by shares in the quarter, for a total of shares.
More recent AxoGen, Inc. (NASDAQ:AXGN) news were published by Seekingalpha.com, Nasdaq.com and Globenewswire.com. The first one has “Is AxoGen A Buy On The Dip?” as a title and was published on October 15, 2018. The next is “New Research: Key Drivers of Growth for AxoGen, Spirit Realty Capital, elf Beauty, Minerva Neurosciences, Par Pacific …” on November 09, 2018. And last was published on October 29, 2018, called “AxoGen, Inc. Reports 2018 Third Quarter Financial Results”.
AxoGen, Inc. (NASDAQ:AXGN) Ratings Coverage
In total 2 analysts cover AxoGen (NASDAQ:AXGN). “Buy” rating has 2, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 2 are the (NASDAQ:AXGN)’s analyst reports since June 26, 2018 according to StockzIntelligence Inc. In Tuesday, June 26 report Leerink Swann maintained it with “Buy” rating and $7000 target. On Tuesday, October 30 the firm has “Overweight” rating given by Cantor Fitzgerald.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.